Biopharmaceutics Classification System Class IV Drugs: Carriers and Barriers
Die Pharmazie · 23.10.2026 · 81 (10)
DOI: 10.31083/pharmazie56776 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Die Pharmazie, online erschienen am 23.10.2026. Verfasst von Yasmin Abouelbaqa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Biopharmaceutics, Drug Carriers. Die Arbeit nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Egyptian Ministry of Higher Education, Mitacs Accelerate Canada.
Abstract (Originalsprache)
Within the Biopharmaceutics Classification System (BCS), Class IV compounds exhibit both low aqueous solubility and low intestinal permeability, placing these compounds among the most formidable challenges in pharmaceutical development. These molecules are frequently subject to efflux–transporter interactions, most notably with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), and undergo extensive pre-systemic cytochrome P450 (CYP450) metabolism, collectively producing poor and erratic oral bioavailability (BA). This review provides a structured narrative synthesis of representative literature on formulation strategies for BCS IV drug delivery. Coverage spans solubility-enhancing and solid-state engineering technologies (cyclodextrins, amorphous solid dispersions, cocrystals, supersaturating systems), lipid-based and nanotechnology-based delivery platforms, transporter- and metabolism-targeted prodrug and permeation–enhancer strategies, alternative administration routes, and computational design tools. Notable marketed successes including Norvir® (ritonavir), Kaletra® (lopinavir), Neoral® (cyclosporine), Venclexta® (venetoclax), and Abraxane® (nab-paclitaxel) demonstrate that BCS IV classification need not preclude clinical and commercial success. This review consolidates and organises these strategies within a unified decision framework intended to serve as a comprehensive resource for pharmaceutical scientists formulating BCS IV compounds. Throughout, this review foregrounds an asymmetry too often left implicit: low solubility is mechanistically well-understood and reliably correctable, whereas the permeability barrier raises three harder questions: whether in vitro permeability predicts in vivo permeability, whether deliberately altering intestinal permeability carries a toxicological cost, and whether most strategies change permeability at all rather than raising exposure by other means.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2H7, Canada.
- Faculty of Veterinary Medicine, Matrouh University, 51744 Matrouh, Egypt.
Förderung
- The Egyptian Ministry of Higher Education
- Mitacs Accelerate Canada
Zitieren
APA
Abouelbaqa, Y., Stephens, N. R., Löbenberg, R., & Davies, N. M. (2026). Biopharmaceutics Classification System Class IV Drugs: Carriers and Barriers. Die Pharmazie, 81(10). https://doi.org/10.31083/pharmazie56776
Vancouver
Abouelbaqa Y, Stephens NR, Löbenberg R, Davies NM. Biopharmaceutics Classification System Class IV Drugs: Carriers and Barriers. Die Pharmazie. 2026;81(10). doi:10.31083/pharmazie56776
BibTeX
@article{Abouelbaqa2026,
author = {Abouelbaqa, Yasmin and Stephens, Nicole R and Löbenberg, Raimar and Davies, Neal M},
title = {Biopharmaceutics Classification System Class IV Drugs: Carriers and Barriers},
journal = {Die Pharmazie},
year = {2026},
volume = {81},
number = {10},
doi = {10.31083/pharmazie56776}
}
EUVIMED